MedPath

Sodium Polystyrene Sulfonate

SPS SUSPENSION Sodium Polystyrene Sulfonate Suspension, USP

Approved
Approval ID

12d48dcf-07bd-4b06-bd6c-7543f1be8357

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 15, 2021

Manufacturers
FDA

CMP Pharma, Inc.

DUNS: 005224175

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

sodium polystyrene sulfonate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code46287-006
Application NumberANDA087859
Product Classification
M
Marketing Category
C73584
G
Generic Name
sodium polystyrene sulfonate
Product Specifications
Route of AdministrationORAL, RECTAL
Effective DateDecember 3, 2020
FDA Product Classification

INGREDIENTS (9)

SODIUM POLYSTYRENE SULFONATEActive
Quantity: 15 g in 60 mL
Code: 1699G8679Z
Classification: ACTIB
ALCOHOLInactive
Quantity: 0.18 mL in 60 mL
Code: 3K9958V90M
Classification: IACT
SACCHARIN SODIUMInactive
Code: SB8ZUX40TY
Classification: IACT
METHYLPARABENInactive
Code: A2I8C7HI9T
Classification: IACT
PROPYLPARABENInactive
Code: Z8IX2SC1OH
Classification: IACT
SORBITOLInactive
Quantity: 21.5 mL in 60 mL
Code: 506T60A25R
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT
MAGNESIUM ALUMINUM SILICATEInactive
Code: 6M3P64V0NC
Classification: IACT

Drug Labeling Information

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 12/3/2020

INDICATION AND USAGE

SPS® Suspension is indicated for the treatment of hyperkalemia.

SPL UNCLASSIFIED SECTION

LOINC: 42229-5Updated: 12/3/2020

CMP Pharma, Inc.
Cation-Exchange Resin
Rx Only

DESCRIPTION SECTION

LOINC: 34089-3Updated: 12/3/2020

DESCRIPTION

Sodium Polystyrene Sulfonate Suspension USP (SPS® Suspension) can be administered orally or in an enema. It is a cherry-flavored suspension containing 15 grams of cation-exchange resin (Sodium Polystyrene Sulfonate USP);21.5 mL of Sorbitol Solution USP (equivalent to approximately 20 grams of Sorbitol); 0.18 mL (0.3%) of Alcohol per 60 mL of suspension. Also contains Purified Water USP; Propylene Glycol USP; Magnesium Aluminum Silicate NF; Sodium Saccharin USP; Methylparaben NF; Propylparaben NF; and flavor.

Sodium polystyrene sulfonate is a benzene, diethenyl-, polymer with ethenylbenzene, sulfonated, sodium salt and has the following structural formula:

![Chemical Structure](/dailymed/image.cfm?name=sps- suspension-01.jpg&id=581279)

The sodium content of the suspension is 1500 mg (65 mEq) per 60 mL. It is a brown, slightly viscous suspension with an in‑vitro exchange capacity of approximately 3.1 mEq (in-vivo approximately 1 mEq) of potassium per 4 mL (1 gram) of suspension. It can be administered orally or in an enema.

CLINICAL PHARMACOLOGY SECTION

LOINC: 34090-1Updated: 12/3/2020

CLINICAL PHARMACOLOGY

As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. For the most part, this action occurs in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable. It commonly approximates the order of 33%, but the range is so large that definitive indices of electrolyte balance must be clearly monitored.

Metabolic data are unavailable.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Sodium Polystyrene Sulfonate - FDA Drug Approval Details